Tagged with Access

Tunisia Hamouda Zaouia, regional manager Africa, Middle East and Turkey, and Khaled Laouiti, general manager Tunisia, Libya and sub-Saharan Africa, stress the important strategic position the African continent has for Pierre Fabre. They describe the company’s approach when tailoring its portfolio to truly target the needs of patients and Pierre Fabre’s…

Canada Stéphane Lassignardie, General Manager of AbbVie Canada, discusses the significant milestones for AbbVie Canada in the past three years, with major product and indication launches, the various initiatives it has introduced to support patients and healthcare practitioners, and the exciting investments it is making into its pipeline. Stéphane, having been…

Bulgaria Zoya Paunova, country director at AstraZeneca Bulgaria, explains how a great combination of an innovative product portfolio with a skilled and dedicated team has turned the local offering into leading brands in the Bulgarian pharmaceutical market and highlights that AstraZeneca’s CSR initiatives are now ranked as the best in Europe.…

Poland Beata Ambroziewicz, board member of the Polish cancer patient coalition, an umbrella organization that encompasses 41 Polish cancer organizations, discusses the challenges and possible solutions in regard to hospital care and market access in the oncology community. She also highlights the importance of a coordinated approach towards the treatment of…

Tunisia Salim Ouertani, business unit manager at AbbVie Tunisia, has been with the affiliate since its beginning in Tunisia when it was spun-off from Abbott in 2013, being in charge of ensuring a smooth transition. Presently, AbbVie’s manager runs ethical operations and is looking forward to supporting more patients suffering from…

Canada Sylvie Pilon, VP and GM at Lundbeck Canada, shares the highlights of her first year leading the Canadian affiliate; the challenges associated with Canada’s complex market access environment, particularly for mental illnesses; Lundbeck’s commitment to supporting patient associations in order to reduce the stigma associated with mental health conditions; and…

Poland Bogna Cichowska-Duma, general director of the Employers’ Association of Innovative Pharmaceutical Companies (INFARMA), the voice of 28 leading innovative companies in Poland, discusses the challenges and opportunities for doing research and business in Poland. Furthermore, she points out the importance of seeing healthcare expenses as investments not solely costs and…

Brazil Heraldo Marchezini, CEO of the Brazilian biotech company Biomm and one of the leading executives in the Brazilian biopharmaceutical sector, provides insights into the eye-catching international partnerships recently signed by this ambitious company and documents Biomm’s vision to develop a balanced portfolio combining very innovative biologicals and leading biosimilars in…

Canada Janice Murray, president of Novartis Pharmaceuticals Canada Inc., highlights the track record of excellence Novartis has enjoyed in Canada as the second largest pharma affiliate in the country, the challenge of adapting to an increasingly uncertain market access environment, and the exciting initiatives through which Novartis is delivering innovations and…

Poland Marcin Czech, deputy minister and undersecretary of state at the Polish Ministry of Health, provides an in-depth perspective on Poland’s drug policy framework and the new medicines policy that aims to integrate pharmacoecomonics to ensure Poland can find an efficient balance between innovative and generic treatments for long-term stability. Furthermore,…

Canada Newly appointed minister of health of Canada, The Honourable Ginette Petitpas Taylor, shares the core tenets of her mandate, the Federal government’s priorities for investment into the Canadian healthcare ecosystem, as well as the strategic significance of the life sciences industry for the country. Healthcare was a core issue on…

Austria Peter Wimmer, country manager of Angelini Austria and Germany, discusses the tailored long-term strategy that this exciting Italian pharmaceutical company is implementing to establish a boutique portfolio and the importance of scientific data in constructing positive relationships throughout the healthcare community. Furthermore, he highlights the reasons Austria is being addressed…